Alpha Capital appointed as financial advisor for CD8 Technology Services' $50M facility development for cell therapy GMP capabilities.

Alpha Capital has been appointed as the exclusive financial advisor for CD8 Technology Services, which is seeking up to $50 million to develop a facility for biologic product manufacturing related to cell therapy. This facility aims to enhance GMP capabilities and expedite manufacturing for clients, including Tevogen Bio, which plans to utilize it for developing off-the-shelf T-cell therapies for infectious diseases and cancers.

October 29, 2024
7 Articles